Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121485 | 0.83 | ALDH1A1 (0.44) | MAPTMEN1KMT2AKLK7ALDH1A1 | |
| SCHEMBL10121480 | 0.83 | ATM (0.36) | ROCK2ROCK1MAPTMEN1KMT2A | |
| SCHEMBL10019901 | 0.77 | MAPT (0.51) | MAPTMEN1KMT2AATMALDH1A1 | |
| SCHEMBL13653026 | 0.76 | KMT2A (0.48) | MAPTMEN1KMT2AATMALDH1A1 | |
| SCHEMBL13624511 | 0.75 | MEN1 (0.45) | MAPTMEN1KMT2AKLK7ATM | |
| SCHEMBL13611346 | 0.75 | MEN1 (0.45) | MAPTMEN1KMT2AKLK7ATM | |
| SCHEMBL10121488 | 0.74 | ITGB3 (0.41) | ROCK2ROCK1 | |
| SCHEMBL1535326 | 0.73 | MAPT (0.52) | MAPTMEN1KMT2AATMALDH1A1 | |
| SCHEMBL13242624 | 0.72 | CA12 (0.46) | MAPTKMT2AALDH1A1 | |
| SCHEMBL17554594 | 0.71 | BCL9 (0.61) | MAPTKMT2AL3MBTL1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | ROCK2 1160/4885ROCK1 505/4885MAPT 1640/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | ROCK2 1160/4885ROCK1 505/4885MAPT 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.